Michael Asbach,

DMSc, PA-C, Psych-CAQ

Michael Asbach

DMSc, PA-C, Psych-CAQ

Associate Director, Interventional Psychiatry, DENT Neurologic Institute

Michael Asbach,

DMSc, PA-C, Psych-CAQ

Associate Director, Interventional Psychiatry, DENT Neurologic Institute

Michael Asbach is the Associate Director of Interventional Psychiatry at DENT Neurologic Institute. He is a clinical professor of psychiatry at Daemen College, D’Youville University, and Rochester Institute of Technology. Dr. Asbach received his master’s in physician assistant studies from Daemen College. His Doctorate of Medical Science degree is with a concentration in healthcare leadership. Dr. Asbach is a member of the American Academy of Physician Assistants and the Association of Physician Assistants in Psychiatry, and he serves as the Chair of Industry Relations for the New York State Society of Physician Assistants. Dr. Asbach is a nationally recognized educator who has provided over 400 lectures on behalf of the pharmaceutical industry and medical education companies.

Michael's Shared Resources

Video: Differentiating Tardive Dyskinesia From Parkinsonism for Accurate Treatment

In this video, Dr. Craig Chepke underscores the importance of distinguishing tardive dyskinesia (TD) from other movement disorders to ensure...
CURATED BY:
Michael Asbach,
DMSc, PA-C, Psych-CAQ

Life with Tardive Dyskinesia: A Patient Journey

Keith Wapniarski's life took a drastic turn after a car accident in 1986, which led to severe migraines and pain....
CURATED BY:
Michael Asbach,
DMSc, PA-C, Psych-CAQ

Promising Therapies for Tardive Dyskinesia: Efficacy and Safety of Valbenazine and Deutetrabenazine

Tardive dyskinesia (TD) is a neurological disorder characterized by involuntary movements, often caused by dopamine receptor antagonists. Vesicular monoamine transporter...
CURATED BY:
Michael Asbach,
DMSc, PA-C, Psych-CAQ

Study Compares Efficacy of Once-Daily and Twice-Daily Deutetrabenazine

Researchers of this study evaluated the bioequivalence of once-daily and twice-daily formulations of deutetrabenazine in a randomized crossover trial involving...
CURATED BY:
Michael Asbach,
DMSc, PA-C, Psych-CAQ

Study Reveals Profound Impact of Tardive Dyskinesia on Caregivers in the United States

Researchers of a survey-based study in the United States involving 162 caregivers, highlight the profound impact of tardive dyskinesia (TD)...
CURATED BY:
Michael Asbach,
DMSc, PA-C, Psych-CAQ

Tardive Dyskinesia Impact Scale Enhances Patient-Centric Assessment of the Movement Disorder

In a recent study, researchers aimed to develop and evaluate the Tardive Dyskinesia Impact Scale (TDIS), a patient-reported outcome measure...
CURATED BY:
Michael Asbach,
DMSc, PA-C, Psych-CAQ
Share